Mechanisms associated with resistance to tamoxifen in estrogen receptor-positive breast cancer (review)
Por:
Viedma-RodríGuez R., Baiza-Gutman L., Salamanca-Gómez F., Diaz-Zaragoza M., Martínez-Hernández G., Esparza-Garrido R.R., Velázquez-Flores M.A., Arenas-Aranda D.
Publicada:
1 jul 2014
Resumen:
Anti-estrogens such as tamoxifen are widely used in the clinic to treat estrogen receptor-positive breast tumors. Patients with estrogen receptor-positive breast cancer initially respond to treatment with anti-hormonal agents such as tamoxifen, but remissions are often followed by the acquisition of resistance and, ultimately, disease relapse. The development of a rationale for the effective treatment of tamoxifen-resistant breast cancer requires an understanding of the complex signal transduction mechanisms. In the present study, we explored some mechanisms associated with resistance to tamoxifen, such as pharmacologic mechanisms, loss or modification in estrogen receptor expression, alterations in co-regulatory proteins and the regulation of the different signaling pathways that participate in different cellular processes such as survival, proliferation, stress, cell cycle, inhibition of apoptosis regulated by the Bcl-2 family, autophagy, altered expression of microRNA, and signaling pathways that regulate the epithelial-mesenchymal transition in the tumor microenvironment. Delineation of the molecular mechanisms underlying the development of resistance may aid in the development of treatment strategies to enhance response and compromise resistance.
Filiaciones:
UNAM, Fac Higher Studies FES Iztacala, Unit Morphol & Funct, Los Reyes Iztacala, State Of Mexico, Mexico
Univ Nacl Autonoma Mexico, Biomed Res Inst IIBM, Mexico City, DF, Mexico
Molecular Genetics Laboratory, Medical Research Unit in Human Genetics, Pediatric Hospital, 330 Cuauhtemoc Avenue, Mexico City 06729, Mexico
All Open Access, Bronze
|